Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onconetix Inc.

3.26
+0.17005.50%
Volume:82.20K
Turnover:266.20K
Market Cap:5.04M
PE:0.00
High:3.32
Open:3.08
Low:3.07
Close:3.09
52wk High:552.50
52wk Low:2.61
Shares:1.55M
Float Shares:1.24M
Volume Ratio:1.68
T/O Rate:6.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-683.3884
EPS(LYR):-1,823.3933
ROE:-1180.06%
ROA:-8.61%
PB:0.85
PE(LYR):0.00

Loading ...

Company Profile

Company Name:
Onconetix Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
5
Office Location:
201 East Fifth Street,Suite 1900,Cincinnati,Ohio,United States
Zip Code:
45202
Fax:
- -
Introduction:
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Directors

Name
Position
Andrew Oakley
Non-Executive Chairman,Lead Independent Director
Simon Tarsh
Independent Director
Timothy R. Ramdeen
Independent Director
Thomas Meier
Director

Shareholders

Name
Position
Karina M. Fedasz
Interim Chief Financial Officer and Interim Chief Executive Officer